Objective: This paper examines the incidence, clinical presentation, and pathophysiology of portal vein thrombosis (PVT) in cirrhosis. Additionally, we have reviewed the literature regarding the current status of medical and interventional radiology management of PVT and have proposed a novel algorithm for the management given different clinical scenarios. Lastly two representative cases displaying endovascular treatment options are provided. Background: Portal vein thrombus in the setting of cirrhosis is an increasingly recognized clinical issue with debate on its pathophysiology, natural course, and optimal treatment. Approximately one-third of patients are asymptomatic, and detection of the thrombus is an incidental finding on imaging performed for other reasons. In 30% to 50% of patients, PVT resolves spontaneously. However, there is increased post-transplant mortality in patients with completely occlusive PVT, therefore effective early revascularization strategies are needed for patients with complete PVT who are expected to undergo liver transplant. Additionally, no consensus has been reached regarding PVT treatment in terms of timing and type of interventions as well as type and duration of anticoagulation. Methods: Computerized literature search as well as discussion with experts in the field. Conclusions: Management of PVT is complex, as many variables affect which treatments can be used. Anticoagulation appears to be the optimal first-line treatment in patients with acute PVT but without bleeding varices or mesenteric ischemia. Minimally invasive treatments include various methods of mechanical thrombectomy, chemical thrombolysis, and transjugular intrahepatic portosystemic shunt (TIPS) placement with or without variceal embolization. Definitive recommendations are difficult due to lack of high quality data and continued research is needed to evaluate the efficacy of different anticoagulants as well as the timing and use of various minimally invasive therapies in specific circumstances. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Objective: This paper examines the incidence, clinical presentation, and pathophysiology of portal vein thrombosis (PVT) in cirrhosis. Additionally, we have reviewed the literature regarding the current status of medical and interventional radiology management of PVT and have proposed a novel algorithm for the management given different clinical scenarios. Lastly two representative cases displaying endovascular treatment options are provided. Background: Portal vein thrombus in the setting of cirrhosis is an increasingly recognized clinical issue with debate on its pathophysiology, natural course, and optimal treatment. Approximately one-third of patients are asymptomatic, and detection of the thrombus is an incidental finding on imaging performed for other reasons. In 30% to 50% of patients, PVT resolves spontaneously. However, there is increased post-transplant mortality in patients with completely occlusive PVT, therefore effective early revascularization strategies are needed for patients with complete PVT who are expected to undergo liver transplant. Additionally, no consensus has been reached regarding PVT treatment in terms of timing and type of interventions as well as type and duration of anticoagulation. Methods: Computerized literature search as well as discussion with experts in the field. Conclusions: Management of PVT is complex, as many variables affect which treatments can be used. Anticoagulation appears to be the optimal first-line treatment in patients with acute PVT but without bleeding varices or mesenteric ischemia. Minimally invasive treatments include various methods of mechanical thrombectomy, chemical thrombolysis, and transjugular intrahepatic portosystemic shunt (TIPS) placement with or without variceal embolization. Definitive recommendations are difficult due to lack of high quality data and continued research is needed to evaluate the efficacy of different anticoagulants as well as the timing and use of various minimally invasive therapies in specific circumstances. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: María Gabriela Delgado; Susana Seijo; Ismael Yepes; Linette Achécar; Maria Vega Catalina; Angeles García-Criado; Juan G Abraldes; Joaquín de la Peña; Rafael Bañares; Agustín Albillos; Jaume Bosch; Juan Carlos García-Pagán Journal: Clin Gastroenterol Hepatol Date: 2012-01-28 Impact factor: 11.382
Authors: Jonathan G Stine; Neeral L Shah; Curtis K Argo; Shawn J Pelletier; Stephen H Caldwell; Patrick G Northup Journal: Liver Transpl Date: 2015-07-01 Impact factor: 5.799
Authors: C Francoz; J Belghiti; V Vilgrain; D Sommacale; V Paradis; B Condat; M H Denninger; A Sauvanet; D Valla; F Durand Journal: Gut Date: 2005-05 Impact factor: 23.059
Authors: Maria Assunta Zocco; Enrico Di Stasio; Raimondo De Cristofaro; Marialuisa Novi; Maria Elena Ainora; Francesca Ponziani; Laura Riccardi; Stefano Lancellotti; Angelo Santoliquido; Roberto Flore; Maurizio Pompili; Gian Lodovico Rapaccini; Paolo Tondi; Giovanni Battista Gasbarrini; Raffaele Landolfi; Antonio Gasbarrini Journal: J Hepatol Date: 2009-04-23 Impact factor: 25.083
Authors: Jessica P E Davis; Amy G Ogurick; Carrie E Rothermel; Min-Woong Sohn; Nicolas M Intagliata; Patrick G Northup Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389
Authors: Mariella Faccia; Maria Elena Ainora; Francesca Romana Ponziani; Laura Riccardi; Matteo Garcovich; Antonio Gasbarrini; Maurizio Pompili; Maria Assunta Zocco Journal: World J Gastroenterol Date: 2019-08-21 Impact factor: 5.742